7,521 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Bought by WINTON GROUP Ltd

WINTON GROUP Ltd acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 7,521 shares of the company’s stock, valued at approximately $1,027,000.

Several other institutional investors have also bought and sold shares of NBIX. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Neurocrine Biosciences by 13.4% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 76,922 shares of the company’s stock valued at $10,623,000 after acquiring an additional 9,086 shares during the last quarter. Segall Bryant & Hamill LLC raised its position in Neurocrine Biosciences by 28.5% during the fourth quarter. Segall Bryant & Hamill LLC now owns 46,870 shares of the company’s stock valued at $6,398,000 after purchasing an additional 10,398 shares during the period. Prudential Financial Inc. lifted its stake in shares of Neurocrine Biosciences by 18.9% in the 4th quarter. Prudential Financial Inc. now owns 210,175 shares of the company’s stock valued at $28,689,000 after purchasing an additional 33,450 shares during the last quarter. Crowley Wealth Management Inc. purchased a new position in shares of Neurocrine Biosciences in the 4th quarter worth approximately $136,000. Finally, Vanguard Group Inc. increased its position in shares of Neurocrine Biosciences by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 10,119,641 shares of the company’s stock valued at $1,381,331,000 after purchasing an additional 122,681 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Activity at Neurocrine Biosciences

In related news, insider Julie Cooke sold 700 shares of Neurocrine Biosciences stock in a transaction on Monday, February 10th. The shares were sold at an average price of $118.28, for a total value of $82,796.00. Following the sale, the insider now owns 18,831 shares of the company’s stock, valued at approximately $2,227,330.68. This trade represents a 3.58 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ingrid Delaet sold 272 shares of the business’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total transaction of $37,563.20. Following the completion of the sale, the insider now directly owns 2,507 shares of the company’s stock, valued at approximately $346,216.70. The trade was a 9.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 233,178 shares of company stock worth $33,906,594 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $113.16 on Friday. Neurocrine Biosciences, Inc. has a one year low of $105.18 and a one year high of $157.98. The stock has a market cap of $11.28 billion, a P/E ratio of 34.40, a P/E/G ratio of 0.77 and a beta of 0.35. The stock has a 50-day moving average of $124.17 and a two-hundred day moving average of $124.94.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. Analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Neurocrine Biosciences announced that its board has approved a share repurchase program on Friday, February 21st that authorizes the company to buyback $500.00 million in shares. This buyback authorization authorizes the company to reacquire up to 4.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

Several research analysts have commented on NBIX shares. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Guggenheim cut their price target on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating on the stock in a report on Monday, February 10th. UBS Group raised their price objective on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a research note on Thursday, January 30th. Canaccord Genuity Group cut their target price on Neurocrine Biosciences from $172.00 to $163.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, Bank of America decreased their price target on Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $165.38.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.